SEENERGIE
Unleash Human Potential
Semaglutide
Shown to cause significant weight loss in overweight and obese individuals by reducing appetite and increasing feeling of fullness.
Active ingredient:
GLP-1 Receptor Agonist
Molecular formula:
C187N291N45O59
Molecular weight:
4113 g/mol
Intake:
Injection
Semaglutide Peptide
Active ingredient:
GLP-1 Receptor Agonist
Molecular formula:
C187N291N45O59
Molecular weight:
4113 g/mol
Intake:
Injection
What is
Semaglutide
Semaglutide is a synthetic analog of the naturally-occurring hormone called glucagon-like peptide-1 (GLP-1). It is produced in the small intestine in response to food intake and plays a critical role in regulating blood sugar levels.
This peptide mimics how GLP-1 works, by binding to and activating the GLP-1 receptor. This results in increased insulin secretion and decreased glucagon secretion, which leads to lower blood glucose levels. In addition, semaglutide peptide slows down gastric emptying, which reduces the rate at which food is absorbed into the bloodstream, leading to a prolonged feeling of fullness.
Semaglutide was originally developed as a medication to treat type 2 diabetes through subcutaneous injection once weekly. It has been shown to improve glycemic control, reduce body weight, and lower the risk of cardiovascular events in people with type 2 diabetes.
It has also been studied for its potential use in weight management. It has been shown to lead to significant weight loss in overweight and obese individuals, with some studies reporting an average weight loss of 15-20% over a 68-week period. The weight loss effects of semaglutide peptide are believed to be due to its ability to reduce appetite and food intake by delaying gastric emptying and increasing feelings of fullness.
Benefits
- Effectively aids in weight loss
- Reduces energy intake
- Regulates appetite and suppresses hunger
- Stops the progression of plaques in blood vessels
- Lowers blood sugar levels and improves insulin sensitivity
- Reduces risk of long-term complications associated with diabetes
- Improves metabolic health
- Lowers the risk of major cardiovascular events such as heart attack and stroke
Protocols
- Content and Potency
Provided as a 2mg lyophilized vial
- Suggested Dosage
Initiation: Semaglutide is typically initiated at a low dose to minimize gastrointestinal side effects and titrated gradually to the maintenance dose.
Initial Dose: Start with 0.25 mg subcutaneously once weekly.
Titration: After 4 weeks, increase the dose to 0.5 mg subcutaneously once weekly.
Maintenance: Continue on the 0.5 mg dose for ongoing management of Type 2 Diabetes Mellitus (DM-2) and/or weight loss.
Duration: Semaglutide is administered once weekly as a long-acting GLP-1 RA.
- Weeks 1-4: 0.25 mg of Semaglutide
- Weeks 5-8: 0.5 mg of Semaglutide
- Weeks 9-12: 1 mg of Semaglutide
- Weeks 13-16 1.7 mg of Semaglutide
- Weeks 17 and onwards: 2.4 mg of Semaglutide
*The dosage of semaglutide can vary depending on factors such as the individual’s medical history, current medications, and response to treatment.
- Restrictions
- Known hypersensitivity to semaglutide, or any component of the formulations
- Personal or family history of medullary thyroid cancer (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- Severe gastrointestinal disease or history of pancreatitis
- Requirements
- Blood test (HbA1c) Test every 3 month to assess glycemic control
- Lipid Profile every 6-12 months to assess cardiovascular risk and guide lipid-lowering therapy
Procedure
- Semaglutide
Reconstitution
- Extract 2 ml of sterile water using a syringe.
- Insert the syringe into the 2 mg peptide vial and inject 2 ml sterile water.
- Shake the vial until the solution is fully dissolved.
- Administration
- Take off the plunger guard and the cap from the tuberculin syringe
- Extract the peptide solution with the tuberculin syringe based on the given dosage.
- Clean the injection site with an alcohol swab.
- Pinch the sanitized skin and insert the needle at a 90-degree angle.
- For next usage
- Refrigerate (2-8 °C) the remaining peptide after each use.
- Before next usage, clean the vial top with an alcohol swab.
- Use a new tuberculin syringe and repeat the administration procedure.
*Common injection sites include the abdomen, thigh, or upper arm. It’s recommended to rotate the injection site with each dose to reduce the risk of skin irritation.
Clinical Research
Study:
Once-Weekly Semaglutide in Adults with overweight or Obesity
Source:
National Center of Biotechnology Information, National Library of Medicine
Results:
The mean change in body weight from baseline to week 68 was -14.9% in the semaglutide group as compared with -2.4% with placebo, for an estimated treatment difference of -12.4 percentage points (95% confidence interval [CI], -13.4 to -11.5; P<0.001). More participants in the semaglutide group than in the placebo group achieved weight reductions of 5% or more (1047 participants [86.4%] vs. 182 [31.5%]), 10% or more (838 [69.1%] vs. 69 [12.0%]), and 15% or more (612 [50.5%] vs. 28 [4.9%]) at week 68 (P<0.001 for all three comparisons of odds). The change in body weight from baseline to week 68 was -15.3 kg in the semaglutide group as compared with -2.6 kg in the placebo group (estimated treatment difference, -12.7 kg; 95% CI, -13.7 to -11.7). Participants who received semaglutide had a greater improvement with respect to cardiometabolic risk factors and a greater increase in participant-reported physical functioning from baseline than those who received placebo.
John P.H. Wilding, D.M., Rachel L. Batterham, M.B., B.S., Ph.D., Salvatore Calanna, Ph.D., Melanie Davies, M.D., Luc F. Van Gaal, M.D., Ph.D., Ildiko Lingvay, M.D., M.P.H., M.S.C.S., Barbara M. McGowan, M.D., Ph.D., Julio Rosenstock, M.D., Marie T.D. Tran, M.D., Ph.D., Thomas A. Wadden, Ph.D., Sean Wharton, M.D., Pharm.D., Koutaro Yokote, M.D., Ph.D., Niels Zeuthen, M.Sc., and Robert F. Kushner, M.D., for the STEP 1 Study Group*. he New England Journal of Medicine
Articles
WEIGHT LOSS Drug Miracle? (Semaglutide Obesity Treatment)
Wegovy (semaglutide 2.4mg) is called a game-changer for folks with Obesity who want to lose weight. Is Wegovy the weight loss answer you’ve been looking for? Can Wegovy help you reverse obesity??
Doctor's Reviews
Ozempic for Weight Loss Without Diabetes
Semaglutide is an injectable glucagon-like peptide-1 Agonist, or short for (GLP-1) agonist that’s administered once a week. It was originally approved in 2017 under the brand name ozempic to control blood sugar in type 2 diabetes.
Doctor of Pharmacy Reviews Ozempic, Semaglutide for Type 2 Diabetes and Weight Loss
The video features a Doctor of Pharmacy reviewing (Semaglutide), a medication used for managing Type 2 diabetes and promoting weight loss. It covers how Ozempic works, its benefits, potential side effects, and the appropriate usage.
3 Semaglutide Tips for Max Weight Loss
In this episode, we dive into the world of weight loss with a focus on Semaglutide, a game-changing tool. Dr. Stirrett shares four insightful tips to help you achieve the maximum potential of Semaglutide for weight loss.
WEIGHT LOSS Drug Miracle? (Semaglutide Obesity Treatment)
Wegovy (semaglutide 2.4mg) is called a game-changer for folks with Obesity who want to lose weight. Is Wegovy the weight loss answer you’ve been looking for? Can Wegovy help you reverse obesity??
